Cytori Will Become Plus Therapeutics, Inc. (GlobeNewswire, Cytori Therapeutics Inc.) - Jul 16, 2019 - The company's initial development focus will be on DocePLUS (formerly ATI-1123) -- a complex, injectable, patented, albumin-stabilized pegylated liposomal docetaxel -- for which a U.S. Phase 1 clinical trial has been completed and published.
Clinical • Regulatory
|